Superscript trial

By: NewsUSA
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

(NewsUSA) - For more details, including important safety information, on VenaSeal, visit: https://www.medtronic.com/breakfree.

Sources

1 Gloviczki P, Comerota AJ, Dalsing MC, et al. The care of patients with varicose veins and associated chronic venous diseases: Clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg. 2011;53(5 Suppl):2S–48S. doi: 10.1016/j.jvs.2011.01.079.

2 Mayo Clinic: Varicose Veinshttps://www.mayoclinic.org/diseases-conditions/varicose-veins/symptoms-causes/syc-20350643

3 National Heart Lung and Blood Institute: Varicose Veins https://www.nhlbi.nih.gov/health/varicose-veins

4 Morrison N, Gibson K, McEnroe S, et al. Randomized trial comparing cyanoacrylate embolization and radiofrequency ablation for incompetent great saphenous veins (VeClose). J Vasc Surg. 2015;61(4):985–994. doi: 10.1016/j.jvs.2014.11.071.

5 Proebstle T, Alm J, Dimitri S, et al. Three-year follow-up results of the prospective European multicenter cohort study on cyanoacrylate embolization for treatment of refluxing great saphenous veins. J Vasc Surg Venous Lymphat Disord. 2021;9(2):329–334. doi: 10.1016/j.jvsv.2020.05.019.

6 Almeida JI, Javier JJ, Mackay EG, Bautista C, Cher DJ, Proebstle TM. Thirty-sixth-month follow-up of first-in-human use of cyanoacrylate adhesive for treatment of saphenous vein incompetence. J Vasc Surg Venous Lymphat Disord. 2017;5(5):658–666. doi: 10.1016/j.jvsv.2017.03.016.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  256.78
+4.89 (1.94%)
AAPL  332.27
+5.70 (1.75%)
AMD  516.13
+12.53 (2.49%)
BAC  62.69
+0.13 (0.21%)
GOOG  335.45
+5.06 (1.53%)
META  648.03
+3.65 (0.57%)
MSFT  495.63
+3.19 (0.65%)
NVDA  218.29
-0.07 (-0.03%)
ORCL  150.28
-2.66 (-1.74%)
TSLA  365.44
+1.88 (0.52%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.